Tags

Type your tag names separated by a space and hit enter

Controlled ovarian hyperstimulation using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in less systemic inflammation than the GnRH-agonist long protocol.
Gynecol Endocrinol. 2007; 23(8):494-6.GE

Abstract

OBJECTIVE

The aim of the study was to investigate whether controlled ovarian hyperstimulation (COH) using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in a lesser degree of systemic inflammation than the GnRH-agonist long protocol.

DESIGN

Prospective, observational study.

PATIENTS AND METHODS

Blood was drawn three times during the COH cycle from patients undergoing the long GnRH-agonist protocol (agonist group) (n = 12) or the multi-dose GnRH-antagonist protocol (antagonist group) (n = 15): the day on which adequate suppression was obtained (agonist group), or day 2 or 3 of the menstrual cycle and before gonadotropin treatment (antagonist group) (Day-0); the day of or prior to administration of human chorionic gonadotropin (Day-hCG); and the day of ovum pick-up (Day-OPU). Levels of sex steroids and serum C-reactive protein (CRP) were compared between the two study groups among the three time points.

RESULTS

While no between-group differences were observed in patient age or ovarian stimulation characteristics, a significantly higher number of oocytes were retrieved in the antagonist compared with the agonist group. In both groups, serum CRP levels were significantly higher on Day-OPU than on Day-hCG and Day-0. While serum CRP levels were higher on Day-hCG than Day-0, the difference was statistically significant only for the agonist group (p < 0.05). Moreover, Day-OPU serum CRP levels were significantly higher in the agonist than in the antagonist subgroup.

CONCLUSION

COH using the multi-dose GnRH-antagonist protocol yields a lesser degree of systemic inflammation, as reflected by CRP levels, than the GnRH-agonist long protocol.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon, Israel. raoulo@barzi.health.gov.ilNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17852411

Citation

Orvieto, Raoul, et al. "Controlled Ovarian Hyperstimulation Using Multi-dose Gonadotropin-releasing Hormone (GnRH) Antagonist Results in Less Systemic Inflammation Than the GnRH-agonist Long Protocol." Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, vol. 23, no. 8, 2007, pp. 494-6.
Orvieto R, Volodarsky M, Hod E, et al. Controlled ovarian hyperstimulation using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in less systemic inflammation than the GnRH-agonist long protocol. Gynecol Endocrinol. 2007;23(8):494-6.
Orvieto, R., Volodarsky, M., Hod, E., Homburg, R., Rabinson, J., Zohav, E., Anteby, E. Y., & Meltcer, S. (2007). Controlled ovarian hyperstimulation using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in less systemic inflammation than the GnRH-agonist long protocol. Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, 23(8), 494-6.
Orvieto R, et al. Controlled Ovarian Hyperstimulation Using Multi-dose Gonadotropin-releasing Hormone (GnRH) Antagonist Results in Less Systemic Inflammation Than the GnRH-agonist Long Protocol. Gynecol Endocrinol. 2007;23(8):494-6. PubMed PMID: 17852411.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Controlled ovarian hyperstimulation using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in less systemic inflammation than the GnRH-agonist long protocol. AU - Orvieto,Raoul, AU - Volodarsky,Michael, AU - Hod,Eduard, AU - Homburg,Roy, AU - Rabinson,Jacob, AU - Zohav,Efraim, AU - Anteby,Eyal Y, AU - Meltcer,Simion, PY - 2007/9/14/pubmed PY - 2010/1/27/medline PY - 2007/9/14/entrez SP - 494 EP - 6 JF - Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology JO - Gynecol Endocrinol VL - 23 IS - 8 N2 - OBJECTIVE: The aim of the study was to investigate whether controlled ovarian hyperstimulation (COH) using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in a lesser degree of systemic inflammation than the GnRH-agonist long protocol. DESIGN: Prospective, observational study. PATIENTS AND METHODS: Blood was drawn three times during the COH cycle from patients undergoing the long GnRH-agonist protocol (agonist group) (n = 12) or the multi-dose GnRH-antagonist protocol (antagonist group) (n = 15): the day on which adequate suppression was obtained (agonist group), or day 2 or 3 of the menstrual cycle and before gonadotropin treatment (antagonist group) (Day-0); the day of or prior to administration of human chorionic gonadotropin (Day-hCG); and the day of ovum pick-up (Day-OPU). Levels of sex steroids and serum C-reactive protein (CRP) were compared between the two study groups among the three time points. RESULTS: While no between-group differences were observed in patient age or ovarian stimulation characteristics, a significantly higher number of oocytes were retrieved in the antagonist compared with the agonist group. In both groups, serum CRP levels were significantly higher on Day-OPU than on Day-hCG and Day-0. While serum CRP levels were higher on Day-hCG than Day-0, the difference was statistically significant only for the agonist group (p < 0.05). Moreover, Day-OPU serum CRP levels were significantly higher in the agonist than in the antagonist subgroup. CONCLUSION: COH using the multi-dose GnRH-antagonist protocol yields a lesser degree of systemic inflammation, as reflected by CRP levels, than the GnRH-agonist long protocol. SN - 1473-0766 UR - https://www.unboundmedicine.com/medline/citation/17852411/Controlled_ovarian_hyperstimulation_using_multi_dose_gonadotropin_releasing_hormone__GnRH__antagonist_results_in_less_systemic_inflammation_than_the_GnRH_agonist_long_protocol_ L2 - https://www.tandfonline.com/doi/full/10.1080/09513590701500994 DB - PRIME DP - Unbound Medicine ER -